AstraZeneca launches $1.5B annual cost-cutting program

· Health · United Kingdom · Sweden

AstraZeneca said Friday it is launching a three-year cost-cutting program aimed at slicing $1.5 billion a year from its cost base, with the savings reinvested in research and development. The move follows a similar savings push by GSK and comes as the Anglo-Swedish drugmaker absorbs late-stage trial failures while pursuing an ambitious $80 billion-by-2030 revenue target. On a call with journalists, leadership hinted at where the cuts and job losses might fall, noting the company is losing patent protection for Farxiga and that R&D could be trimmed and trials shifted to emerging markets. The restructuring puts pressure on AstraZeneca's pipeline spending at a time when several large pharmaceutical companies are trimming costs to protect margins ahead of patent expirations.

Why it matters：The program shows how large drugmakers are trading R&D breadth for margin protection as patent cliffs approach, which could reshape where trials are run and which pipeline assets survive.

Key points

  • The three-year program targets $1.5 billion in annual savings, reinvested in R&D.
  • AstraZeneca cited loss of patent protection for Farxiga among the pressures.
  • Leadership said R&D cuts and trial shifts to emerging markets are possible.

Sources (original reporting)

More stories from this day